FDA approves Opdivo, Yervoy combo for previously untreated unresectable MPM

This article was originally published here

This approval is based on a pre-specified interim analysis from the Phase 3 CheckMate -743 trial in which Opdivo + Yervoy (n=303) demonstrated superior overall survival (OS) versus

The post FDA approves Opdivo, Yervoy combo for previously untreated unresectable MPM appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply